Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Plague Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Plague Overview | 9 | 1 |
| Pipeline Products for Plague Comparative Analysis | 10 | 1 |
| Plague Therapeutics under Development by Companies | 11 | 1 |
| Plague Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Plague Pipeline Products Glance | 13 | 3 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Unknown Stage Products | 15 | 1 |
| Plague Products under Development by Companies | 16 | 1 |
| Plague Products under Investigation by Universities/Institutes | 17 | 1 |
| Plague Companies Involved in Therapeutics Development | 18 | 9 |
| Aradigm Corporation | 18 | 1 |
| AvidBiotics Corp. | 19 | 1 |
| Endacea, Inc. | 20 | 1 |
| Grifols, S.A. | 21 | 1 |
| iBio, Inc. | 22 | 1 |
| Mucosis B.V. | 23 | 1 |
| Syntiron LLC | 24 | 1 |
| Takeda Pharmaceutical Company Limited | 25 | 1 |
| Tetraphase Pharmaceuticals Inc. | 26 | 1 |
| Plague Therapeutics Assessment | 27 | 10 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Combination Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Drug Profiles | 37 | 28 |
| (plague + small pox) vaccine Drug Profile | 37 | 1 |
| anthrax + plague vaccine Drug Profile | 38 | 1 |
| ARD-3100 Drug Profile | 39 | 4 |
| ARD-3150 Drug Profile | 43 | 5 |
| ciprofloxacin hydrochloride Drug Profile | 48 | 1 |
| L-97-1 Drug Profile | 49 | 2 |
| plague vaccine Drug Profile | 51 | 1 |
| plague vaccine Drug Profile | 52 | 1 |
| plague vaccine Drug Profile | 53 | 1 |
| plague vaccine Drug Profile | 54 | 1 |
| plague vaccine Drug Profile | 55 | 1 |
| plague vaccine Drug Profile | 56 | 1 |
| plague vaccine Drug Profile | 57 | 1 |
| plague vaccine 2 Drug Profile | 58 | 1 |
| pneumonic plaque vaccine Drug Profile | 59 | 1 |
| Recombinant Protein for Pneumonic Plague Drug Profile | 60 | 1 |
| Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague Drug Profile | 61 | 1 |
| TP-271 Drug Profile | 62 | 2 |
| Yersinia pestis vaccine Drug Profile | 64 | 1 |
| Plague Dormant Projects | 65 | 1 |
| Plague Discontinued Products | 66 | 1 |
| Plague Product Development Milestones | 67 | 2 |
| Featured News &Press Releases | 67 | 1 |
| Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague | 67 | 1 |
| May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague | 68 | 1 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |